DK3947685T3 - Oligonukleotidbaseret terapi mod ulcerøs colitis - Google Patents

Oligonukleotidbaseret terapi mod ulcerøs colitis Download PDF

Info

Publication number
DK3947685T3
DK3947685T3 DK20760858.9T DK20760858T DK3947685T3 DK 3947685 T3 DK3947685 T3 DK 3947685T3 DK 20760858 T DK20760858 T DK 20760858T DK 3947685 T3 DK3947685 T3 DK 3947685T3
Authority
DK
Denmark
Prior art keywords
oligonucleotide
ulcerative colitis
based therapy
therapy against
against ulcerative
Prior art date
Application number
DK20760858.9T
Other languages
English (en)
Inventor
Peter Zerhouni
Pernilla Sandwall
Thomas Knittel
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Application granted granted Critical
Publication of DK3947685T3 publication Critical patent/DK3947685T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/35Special therapeutic applications based on a specific dosage / administration regimen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK20760858.9T 2019-08-24 2020-08-21 Oligonukleotidbaseret terapi mod ulcerøs colitis DK3947685T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1912191.2A GB201912191D0 (en) 2019-08-24 2019-08-24 New therapy
PCT/EP2020/073566 WO2021037764A1 (en) 2019-08-24 2020-08-21 Oligonucleotide-based therapy for ulcerative colitis

Publications (1)

Publication Number Publication Date
DK3947685T3 true DK3947685T3 (da) 2022-08-08

Family

ID=68108901

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20760858.9T DK3947685T3 (da) 2019-08-24 2020-08-21 Oligonukleotidbaseret terapi mod ulcerøs colitis

Country Status (19)

Country Link
US (1) US20220378818A1 (da)
EP (1) EP3947685B1 (da)
JP (1) JP2022545692A (da)
KR (2) KR102592716B1 (da)
CN (1) CN114599376A (da)
AU (1) AU2020335171A1 (da)
BR (1) BR112022002612A2 (da)
CA (1) CA3151203A1 (da)
DK (1) DK3947685T3 (da)
ES (1) ES2925460T3 (da)
GB (1) GB201912191D0 (da)
HR (1) HRP20220999T1 (da)
HU (1) HUE059642T2 (da)
LT (1) LT3947685T (da)
PL (1) PL3947685T3 (da)
PT (1) PT3947685T (da)
RS (1) RS63640B1 (da)
SI (1) SI3947685T1 (da)
WO (1) WO2021037764A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202018468D0 (en) * 2020-11-24 2021-01-06 Index Pharmaceuticals Ab New therapy
EP4147688A1 (en) * 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP2596806A1 (en) * 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3

Also Published As

Publication number Publication date
KR102592716B1 (ko) 2023-10-20
SI3947685T1 (sl) 2022-09-30
US20220378818A1 (en) 2022-12-01
GB201912191D0 (en) 2019-10-09
WO2021037764A1 (en) 2021-03-04
HRP20220999T1 (hr) 2022-11-11
LT3947685T (lt) 2022-08-25
RS63640B1 (sr) 2022-10-31
ES2925460T3 (es) 2022-10-18
HUE059642T2 (hu) 2022-12-28
CA3151203A1 (en) 2021-03-04
EP3947685A1 (en) 2022-02-09
AU2020335171A1 (en) 2022-02-24
JP2022545692A (ja) 2022-10-28
KR20230148402A (ko) 2023-10-24
KR20220050927A (ko) 2022-04-25
PT3947685T (pt) 2022-08-18
PL3947685T3 (pl) 2022-11-21
EP3947685B1 (en) 2022-07-13
CN114599376A (zh) 2022-06-07
BR112022002612A2 (pt) 2022-05-03

Similar Documents

Publication Publication Date Title
DK3283527T3 (da) Kombinationsterapi mod cancer
DK3423087T3 (da) Kombinationsterapi mod cancer
DK3212670T3 (da) Kombinationsterapi mod cancer
DK3368544T3 (da) Peptidmakrocykler mod Acinetobacter baumannii
DK3552652T4 (da) Kateterindretninger med ventiler
DK3271389T3 (da) Neutraliserende antistoffer mod gp120 og anvendelse deraf
DK3262066T4 (da) Genterapi
DK3606519T3 (da) ASK1-inhibitorforbindelser og anvendelser deraf
DK3119437T3 (da) Genterapi mod retinitis pigmentosa
BR112018005409A2 (pt) terapêutica de glicodirecionamento.
DK3256169T3 (da) Optimeret RPE65-promotor og kodende sekvenser
DK3866850T3 (da) Kombinationsterapi mod melanom
PL3773715T3 (pl) Mirikizumab w leczeniu wrzodziejącego zapalenia jelita grubego
DK3393478T3 (da) Kombinationsterapi
PL3362144T3 (pl) Modułowe urządzenie do intensywnej terapii
BR112018000204A2 (pt) métodos de tratamento de colite
DK3277284T3 (da) Hidtil ukendte terapier mod kræft
GB2555997B (en) Downhole acoustic source localization
DK3947685T3 (da) Oligonukleotidbaseret terapi mod ulcerøs colitis
IL279917A (en) Treating ulcerative colitis with brazikumab
DK3315131T3 (da) Terapeutisk middel mod fibrose
DK3744306T3 (da) Spakabinetfastgørelse
HK1251176A1 (zh) 腹膜治療液
DK3580182T3 (da) Vandbehandling
DK3352735T3 (da) Olanzapinformuleringer med langvarig frigivelse